Predictors of serum levels of high sensitivity C-reactive protein and systolic blood pressure in overweight and obese nondiabetic women in Tehran: A cross-sectional study

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 1, 2011, Pages 41-47

  Neyestani, Tirang R ^a,b   Salekzamani, Shabnam ^a   Kalayi, Ali ^a   Alavi Majd, Hamid ^a   Houshiarrad, Anahita ^a   Nikooyeh, Bahareh ^a   Shariatzadeh, Nastaran ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b National Nutrition and Food Technology Research Institute Tehran   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; BLOOD PRESSURE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; IRAN; MIDDLE AGED; OBESITY; OVERWEIGHT; PROGNOSIS; SUBSTRATE SPECIFICITY; WAIST CIRCUMFERENCE;

EID: 79955504583     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2010.0075     Document Type: Article

References (62)

1. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond) 2008;32(Suppl 7):S120-S126.
2. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008;32:1431-1437.
3. Das S. Obesity: A global problem. J Hum Nutr Diet. 2008;21:179.
4. Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, Kamgar M, Gouya M, Abbasi M. Third national Surveillance of Risk Factors of Non- Communicable Diseases (SuRFNCD-2007) in Iran: Methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health 2009;9:167.
5. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesityrelated hypertension. Hypertension 2006;48:787-796. (Pubitemid 44610980)
6. Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, Ounpuu S, Yusuf S, for the INTERHEART Investigators in Africa. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005;112:3554-3561. (Pubitemid 43739532)
7. Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, Caccia C, Johnson J, Waugh R, Sherwood A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: The ENCORE study. Arch Intern Med 2010;170:126-135.
8. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010;74:213-220.
9. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: The link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577-584.
10. Young I, Rifai N. High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem 2009;55:201-202.
11. Ridker PM. C-reactive protein: Eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 2009;55:209-215.
12. Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A. C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: The JACC Study. Atherosclerosis 2009; 207:291-297.
13. Wee CC, Mukamal KJ, Huang A, Davis RB, McCarthy EP, Mittleman MA. Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) 2008;16:875-880. (Pubitemid 351465646)
14. Gowri V, Rizvi SG, Squib S, Al Futaisi A. High-sensitivity Creactive protein is a marker of obesity and not of polycystic ovary syndrome per se. Fertil Steril 2010 (in press).
15. Hickling S, Hung J, Knuiman M, Divitini M, Beilby J. Are the associations between diet and C-reactive protein independent of obesity? Prev Med 2008;47:71-76.
16. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres J-P. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21: 961-967. (Pubitemid 34168653)
17. Oliveira A, Lopes C, Severo M, Rodriguez-Artalejo F, Barros H. Body fat distribution and C-reactive protein- a principal component analysis. Nutr Metab Cardiovasc Dis 2010 (in press).
18. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of Creactive protein in response to inflammatory cytokines by human adipocytes: Linking obesity to vascular inflammation. J Am Coll Cardiol 2005;46:1112-1113. (Pubitemid 41316523)
19. Calabro P, Golia E, Maddaloni V, Malvezzi M, Casillo B, Marotta C, Calabro R, Golino P. Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 2009;4:25-34.
20. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, Levy Y, Brook GJ, Aronson D. Association between elevated liver enzymes and C-reactive protein: Possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25: 193-197. (Pubitemid 40054275)
21. Chou HH, Hsu LA, Liu CJ, Teng MS, Wu S, Ko YL. Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. Metabolism 2010;59:824-830.
22. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003;13:674-682. (Pubitemid 37346407)
23. Lapice E, Maione S, Patti L, Cipriano P, Rivellese AA, Riccardi G, Vaccaro O. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care 2009;32:1734-1736.
24. Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet 2010;281:1009-1014.
25. Kalantari N, Ghafarpour, M. National Comprehensive Study on Household Food Consumption Pattern and Nutritional Status, IR Iran, 2001-2003. National Report; 2005.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
27. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen C-L, Lai M-Y, Chen P-J, Kao J-H, Chen D-S. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008;28:271-277. (Pubitemid 351201041)
28. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, Lindgarde F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol 2004;24:1498-1502. (Pubitemid 39050447)
29. Koren MS, Purnell JQ, Breen PA, Matthys CC, Callahan HS, Weigle DS. Plasma C-reactive protein concentration is not affected by isocaloric dietary fat reduction. Nutrition 2006;22:444-448. (Pubitemid 43374627)
30. Due A, Toubro S, Stender S, Skov AR, Astrup A. The effect of diets high in protein or carbohydrate on inflammatory markers in overweight subjects. Diabetes Obes Metab 2005; 7:223-229. (Pubitemid 40542812)
31. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti A, MacFadyen J. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-1182.
32. Suganami T, Ogawa Y. Adipose tissue macrophages: Their role in adipose tissue remodeling. J Leukoc Biol 2010;88:33-39.
33. Festa A, D'Agostino R, Jr., Williams K, Karter AJ, Mayer- Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-1415. (Pubitemid 32977855)
34. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook J, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes 2004;28:674-679. (Pubitemid 38580975)
35. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factoralpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-4200. (Pubitemid 27525539)
36. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin- 6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850. (Pubitemid 28496456)
37. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369. (Pubitemid 36158034)
38. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang C, Rumboldt Z, Onen C, Lisheng L. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 2005;366:1640-1649. (Pubitemid 41552419)
39. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 2005;183:308-315. (Pubitemid 41579282)
40. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827.
41. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 2010;34:949-959.
42. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol 2010;31:228-235.
43. Wiest R, Moleda L, Farkas S, Scherer M, Kopp A, Wonckhaus U, Buchler C, Scholmerich J, Schaffler A. Splanchnic concentrations and postprandial release of visceral adipokines. Metabolism 2010;59:664-670.
44. Bell AC, Adair LS, Popkin BM. Understanding the role of mediating risk factors and proxy effects in the association between socio-economic status and untreated hypertension. Soc Sci Med 2004;59:275-283. (Pubitemid 38534257)
45. Azizi, F, Ghanbarian, A, Madjid, M, Rahmani, M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999-2000. J Hum Hypertens 2002;16:305-312. (Pubitemid 34537398)
46. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001;25:1327-1331. (Pubitemid 32835450)
47. Jensen MD. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 2006;14(Suppl 1):20S-24S.
48. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S57-S63.
49. Shuger SL, Sui X, Church TS, Meriwether RA, Blair SN. Body mass index as a predictor of hypertension incidence among initially healthy normotensive women. Am J Hypertens 2008;21:613-619. (Pubitemid 351733374)
50. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000;8:605-619.
51. Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg- Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009;54:84-90.
52. Brandon LJ, Mullis RM, Jonnalagadda SS, Hughes MH. Relationships and CHD risks of BMI, lipoproteins, lipids, and blood pressure in African-American men and women. Prev Med 2005;40:349-354. (Pubitemid 39468600)
53. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: Clinical action thresholds. Am J Clin Nutr 2002;76:743-749.
54. Olinto MT, Nacul LC, Gigante DP, Costa JS, Menezes AM, Macedo S. Waist circumference as a determinant of hypertension and diabetes in Brazilian women: A populationbased study. Public Health Nutr 2004;7:629-635. (Pubitemid 39049977)
55. Harris MM, Stevens J, Thomas N, Schreiner P, Folsom AR. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: The ARIC study. Atherosclerosis Risk in Communities Study. Obes Res 2000; 8:516-524.
56. Genovesi S, Antolini L, Giussani M, Brambilla P, Barbieri V, Galbiati S, Mastriani S, Sala V, Valsecchi MG, Stella A. Hypertension, prehypertension, and transient elevated blood pressure in children: Association with weight excess and waist circumference. Am J Hypertens 2010;23:756-761.
57. Kovacs VA, Gabor A, Fajcsak Z, Martos E. Role of waist circumference in predicting the risk of high blood pressure in children. Int J Pediatr Obes 2010;5:143-150.
58. Majane OH, Norton GR, Maseko MJ, Makaula S, Crowther N, Paiker J, Thijs L, Brooksbank R, Sareli P, Staessen JA, Woodiwiss AJ. The association of waist circumference with ambulatory blood pressure is independent of alternative adiposity indices. J Hypertens 2007;25:1798-1806. (Pubitemid 47356619)
59. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension 2003;42:878-884. (Pubitemid 37413724)
60. Janghorbani M, Amini M, Gouya MM, Delavari A, Alikhani S, Mahdavi A. Nationwide survey of prevalence and risk factors of prehypertension and hypertension in Iranian adults. J Hypertens 2008;26:419-426. (Pubitemid 351317249)
61. Bahrami H, Sadatsafavi M, Pourshams A, Kamangar F, Nouraei M, Semnani S, Brennan P, Boffetta P, Malekzadeh R. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health 2006; 6:158.
62. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010; doi: 10.2337/dc09-2062.